The news came days after Karuna stated that KarXT reached its main goal in a clinical trial and showed efficacy in reducing psychosis.
Royalty will receive 25% of Ionis’ Spinraza royalty payments through 2027 and it will increase to 45% of royalty payments in 2028 on up to $1.5 billion in annual sales.
MM+M is proud to announce the fourth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators.
Get the most out of
Register for free and enjoy unlimited access to:
